Gleiss Lutz advises MitrAssist on Series B financing round for medical technology startup AdjuCor
Gleiss Lutz has advised MitrAssist Holdings Limited on its investment as lead investor in medical technology startup AdjuCor. AdjuCor will receive EUR 29 million in the Series B financing round.
AdjuCor with registered office in Munich is developing an innovative, implantable and minimally invasive heart assist device for treating patients suffering from heart failure. AdjuCor will use this capital increase to fund the finalisation of its product development, complete the production facilities and execute its premarket clinical trials in Europe.
MitrAssist was founded in 2009 in Israel and has meanwhile become a multinational company specialising in cardiovascular technologies. The investors of MitrAssist include Chinese companies and private equity firms such as Fosun Pharma, Centurium Capital, CICC Capital, CITIC Capital and insurance company Ping-An.
Gleiss Lutz has a market leading Asia desk and frequently advises Chinese investors on projects in Europe, most recently including a group of strategic and financial investors on their attempted acquisition of Huba Control from Siemens and a consortium led by FountainVest on the acquisition of SPT.
The following team of Gleiss Lutz lawyers headed by Dr. Michael Burian (partner, lead) and Dr. Anselm Christiansen advised MitrAssist: Dr. Yixiao Li (Stuttgart), Dr. Martin Viciano Gofferje (partner), Dr. Torsten Spiegel (Berlin), Kyoko Mogi (Stuttgart, all M&A), Dr. Jacob von Andreae (partner), Aylin Hoffs (both Public Law, Düsseldorf), Dr. Rut Steinhauser (partner), Josefine Chakrabarti (both Employment, Berlin), Michael Neher (Real Estate, Frankfurt) und Simon Wegmann (data protection, Berlin).